Elevation of tumor necrosis factor-α induces the overproduction of postprandial intestinal apolipoprotein B48-containing very low-density lipoprotein particles: Evidence for related gene expression of inflammatory, insulin and lipoprotein signaling in enterocytes

Experimental Biology and Medicine

Volumn 235, Issue 2, 2010, Pages 199-205

  Qin, Bolin ^a,b   Dawson, Harry ^a   Anderson, Richard A ^a  

^a BELTSVILLE HUMAN NUTRITION RESEARCH CENTER   (United States)

^b Integrity Nutraceuticals International   (United States)

Author keywords

Chylomicrons and VLDL1 apoB48; Intestinal gene expression; TNF

Indexed keywords

APOLIPOPROTEIN B48; CD36 ANTIGEN; CHYLOMICRON; INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; LIPOPROTEIN; LYMPHOTOXIN; MESSENGER RNA; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; STEROL REGULATORY ELEMENT BINDING PROTEIN; TUMOR NECROSIS FACTOR ALPHA; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY FAT; CELL ISOLATION; CONTROLLED STUDY; ENZYME SYNTHESIS; GENE EXPRESSION; HAMSTER; INFLAMMATION; INSULIN SENSITIVITY; INTESTINE CELL; MALE; NONHUMAN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALS; APOLIPOPROTEIN B-48; BASE SEQUENCE; CARRIER PROTEINS; CHYLOMICRONS; CRICETINAE; DNA PRIMERS; ENTEROCYTES; GENE EXPRESSION; INFLAMMATION MEDIATORS; INSULIN; INSULIN RECEPTOR SUBSTRATE PROTEINS; LIPOPROTEINS, VLDL; MALE; MESOCRICETUS; PPAR GAMMA; PTEN PHOSPHOHYDROLASE; RECEPTOR, INSULIN; RNA, MESSENGER; SCAVENGER RECEPTORS, CLASS B; SIGNAL TRANSDUCTION; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TUMOR NECROSIS FACTOR-ALPHA;

CRICETINAE;

EID: 77649143625     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1258/ebm.2009.009169     Document Type: Article

References (43)

1. Winkler G, Salamon F, Harmos G, Salamon D, Speer G, Szekeres O, Hajos P, Kovacs M, Simon K, Cseh K. Elevated serum tumor necrosis factor-alpha concentrations and bioactivity in Type 2 diabetics and patients with android type obesity. Diabetes Res Clin Pract 1998;42:169-74
2. Haus JM, Kashyap SR, Kasumov T, Zhang R, Kelly KR, DeFronzo RA, Kirwan JP. Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance. Diabetes 2009;58:337-43
3. Carey AL, Bruce CR, Sacchetti M, Anderson MJ, Olsen DB, Saltin B, Hawley JA, Febbraio MA. Interleukin-6 and tumor necrosis factor-alpha are not increased in patients with Type 2 diabetes: evidence that plasma interleukin-6 is related to fat mass and not insulin responsiveness. Diabetologia 2004;47:1029-37
4. Dandona P, Weinstock R, Thusu K, bdel-Rahman E, Aljada A, Wadden T. Tumor necrosis factor-alpha in sera of obese patients: fall with weight loss. J Clin Endocrinol Metab 1998;83:2907-10
5. Feingold KR, Grunfeld C. Tumor necrosis factor-alpha stimulates hepatic lipogenesis in the rat in vivo. J Clin Invest 1987;80:184-90
6. Feingold KR, Soued M, Adi S, Staprans I, Shigenaga J, Doerrler W, Moser A, Grunfeld C. Tumor necrosis factor-increased hepatic very-low-density lipoprotein production and increased serum triglyceride levels in diabetic rats. Diabetes 1990;39:1569-74
7. Qin B, Qiu W, Avramoglu RK, Adeli K. Tumor necrosis factor-alpha induces intestinal insulin resistance and stimulates the overproduction of intestinal apolipoprotein B48-containing lipoproteins. Diabetes 2007;56:450- 61
8. Qin B, Anderson RA, Adeli K. Tumor necrosis factor-alpha directly stimulates the overproduction of hepatic apolipoprotein B100-containing VLDL via impairment of hepatic insulin signaling. Am J Physiol Gastrointest Liver Physiol 2008;294:G1120-9
9. Federico LM, Naples M, Taylor D, Adeli K. Intestinal insulin resistance and aberrant production of apolipoprotein B48 lipoproteins in an animal model of insulin resistance and metabolic dyslipidemia: evidence for activation of protein tyrosine phosphatase-1B, extracellular signal-related kinase, and sterol regulatory element-binding protein-1c in the fructose-fed hamster intestine. Diabetes 2006;55:1316-26
10. Haidari M, Leung N, Mahbub F, Uffelman KD, Kohen-Avramoglu R, Lewis GF, Adeli K. Fasting and postprandial overproduction of intestinally derived lipoproteins in an animal model of insulin resistance. Evidence that chronic fructose feeding in the hamster is accompanied by enhanced intestinal de novo lipogenesis and ApoB48-containing lipoprotein overproduction. J Biol Chem 2002;277:31646-55
11. Mangat R, Su J, Scott PG, Russell JC, Vine DF, Proctor SD. Chylomicron and apoB48 metabolism in the JCR:LA corpulent rat, a model for the metabolic syndrome. Biochem Soc Trans 2007;35:477-81
12. Zoltowska M, Ziv E, Delvin E, Sinnett D, Kalman R, Garofalo C, Seidman E, Levy E. Cellular aspects of intestinal lipoprotein assembly in Psammomys obesus: a model of insulin resistance and type 2 diabetes. Diabetes 2003;52:2539-45
13. Mero N, Malmstrom R, Steiner G, Taskinen MR, Syvanne M. Postprandial metabolism of apolipoprotein B-48- and B-100-containing particles in type 2 diabetes mellitus: relations to angiographically verified severity of coronary artery disease. Atherosclerosis 2000; 150:167-77
14. Welty FK, Lichtenstein AH, Barrett PH, Dolnikowski GG, Schaefer EJ. Human apolipoprotein (Apo) B-48 and ApoB-100 kinetics with stable isotopes. Arterioscler Thromb Vasc Biol 1999;19:2966-74
15. Zheng C, Ikewaki K, Walsh BW, Sacks FM. Metabolism of apoB lipoproteins of intestinal and hepatic origin during constant feeding of small amounts of fat. J Lipid Res 2006;47:1771-9
16. Grimble RF. Inflammatory status and insulin resistance. Curr Opin Clin Nutr Metab Care 2002;5:551-9
17. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, Gallimore JR, Pepys MB. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000;321:199-204
18. Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM. Tumor necrosis factor alpha inhibits signaling from the insulin receptor. Proc Natl Acad Sci USA 1994;91:4854-8
19. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-26
20. Ye JM, Doyle PJ, Iglesias MA, Watson DG, Cooney GJ, Kraegen EW. Peroxisome proliferator-activated receptor (PPAR)-alpha activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: comparison with PPAR-gamma activation. Diabetes 2001;50:411-7
21. Goulinet S, Chapman MJ. Plasma lipoproteins in the golden Syrian hamster (Mesocricetus auratus): heterogeneity of apoB- and apoA-I containing particles. J Lipid Res 1993;34:943-59
22. Qin B, Oshida Y, Li P, Kubota M, Nagasaki M, Sato Y. Voluntary running improves in vivo insulin resistance in high-salt diet fed rats. Exp Biol Med (Maywood) 2007;232:1330-7
23. Steiner G, Haynes FJ, Yoshino G, Vranic M. Hyperinsulinemia and vivo very-low-density lipoprotein-triglyceride kinetics. Am J Physiol 1984;246:E187-92
24. Qin B, Polansky MM, Sato Y, Adeli K, Anderson RA. Cinnamon extract inhibits the postprandial overproduction of apolipoprotein B48-containing lipoproteins in fructose-fed animals. J Nutr Biochem 2009;20:901-8
25. Adiels M, Boren J, Caslake MJ, Stewart P, Soro A, Westerbacka J, Wennberg B, Olofsson SO, Packard C, Taskinen MR. Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia. Arterioscler Thromb Vasc Biol 2005;25:1697-703
26. Rollins BJ. Chemokines. Blood 1997;90:909-28
27. Rotter V, Nagaev I, Smith U. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem 2003;278:45777-84
28. Leslie NR, Downes CP. PTEN: The down side of PI 3-kinase signalling. Cell Signal 2002;14:285-95
29. Lo YT, Tsao CJ, Liu IM, Liou SS, Cheng JT. Increase of PTEN gene expression in insulin resistance. Horm Metab Res 2004;36:662-6
30. Nauli AM, Nassir F, Zheng S, Yang Q, Lo CM, Vonlehmden SB, Lee D, Jandacek RJ, Abumrad NA, Tso P. CD36 is important for chylomicron formation and secretion and may mediate cholesterol uptake in the proximal intestine. Gastroenterology 2006;131:1197-207
31. Chen M, Yang YK, Loux TJ, Georgeson KE, Harmon CM. The role of hyperglycemia in FAT/CD36 expression and function. Pediatr Surg Int 2006;22:647-54
32. Poirier H, Degrace P, Niot I, Bernard A, Besnard P. Localization and regulation of the putative membrane fatty-acid transporter (FAT) in the small intestine. Comparison with fatty acid-binding proteins (FABP). Eur J Biochem 1996;238:368-73
33. Drover VA, Abumrad NA. CD36-dependent fatty acid uptake regulates expression of peroxisome proliferator activated receptors. Biochem Soc Trans 2005;33:311-5
34. Ruan H, Hacohen N, Golub TR, Van PL, Lodish HF. Tumor necrosis factor-alpha suppresses adipocyte-specific genes and activates expression of preadipocyte genes in 3T3-L1 adipocytes: nuclear factor-kappaB activation by TNF-alpha is obligatory. Diabetes 2002;51: 1319-36
35. Zhao SP, Dong SZ. Effect of tumor necrosis factor alpha on cholesterol efflux in adipocytes. Clin Chim Acta 2008;389:67-71
36. Hussain MM. A proposed model for the assembly of chylomicrons. Atherosclerosis 2000;148:1-15
37. Lin MC, Gordon D, Wetterau JR. Microsomal triglyceride transfer protein (MTP) regulation in HepG2 cells: insulin negatively regulates MTP gene expression. J Lipid Res 1995;36:1073-81
38. Gleeson A, Anderton K, Owens D, Bennett A, Collins P, Johnson A, White D, Tomkin GH. The role of microsomal triglyceride transfer protein and dietary cholesterol in chylomicron production in diabetes. Diabetologia 1999;42:944-8
39. Phillips C, Bennett A, Anderton K, Owens D, Collins P, White D, Tomkin GH. Intestinal rather than hepatic microsomal triglyceride transfer protein as a cause of postprandial dyslipidemia in diabetes. Metabolism 2002;51:847-52
40. Foufelle F, Ferre P. New perspectives in the regulation of hepatic glycolytic and lipogenic genes by insulin and glucose: a role for the transcription factor sterol regulatory element binding protein-1c. Biochem J 2002;366:377-91
41. Sewter C, Berger D, Considine RV, Medina G, Rochford J, Ciaraldi T, Henry R, Dohm L, Flier JS, O'Rahilly S, Vidal-Puig AJ. Human obesity and type 2 diabetes are associated with alterations in SREBP1 isoform expression that are reproduced ex vivo by tumor necrosis factor-alpha. Diabetes 2002;51:1035-41
42. Shimomura I, Bashmakov Y, Horton JD. Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. J Biol Chem 1999;274:30028-32
43. Bjorkegren J, Packard CJ, Hamsten A, Bedford D, Caslake M, Foster L, Shepherd J, Stewart P, Karpe F. Accumulation of large very low density lipoprotein in plasma during intravenous infusion of a chylomicron-like triglyceride emulsion reflects competition for a common lipolytic pathway. J Lipid Res 1996;37:76-86